Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan vs Rituximab in Idiopathic Membranous Nephropathy
NCT04154787Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of Iptacopan in idiopathic membranous nephropathy (IMN), sponsored by Novartis. Started Nov 2019; status: terminated.
02
Drugs
Iptacopan
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT04154787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154787.